Generic drugmaker Mylan has reached a settlement with Roche for the launch of its biosimilar version of  Herceptin ( the Roches top-selling breast cancer drug) in major markets.

Herceptin is one of the world’s most successful antibody drugs and has been a mainstay of Roche profits for many years.

Mylan will ( as soon as the terms of the deal and the dates of the launch will be disclesed) will launch its biosimilar product in different markets.

Trastuzumab is already sold by Mylan and its Indian partner Biocon in 14 emerging markets and the medicine has been submitted for approval in Europe and the United States.

Roche is also facing biosimilar competition to its blood cancer drug Rituxan.

Source: Reuters